Skip to main content

Morgan Stanley Raises PT On Costamare To $22

Joe Young

May 27, 2011 6:47am Comments

Morgan Stanley has raised the price target on Costamare (NYSE: CMRE) to $22 and maintains its Overweight rating.

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

View Comments and Join the Discussion!

View the discussion thread.

Posted-In: costamare Morgan Stanley Price Target Analyst Ratings

Need analyst data?
Click here to see licensing options.

Latest Ratings

View the Latest Analytics Ratings

1	LLY: Eli Lilly Co. Q2 FY2025 Earnings Transcript
2	TMUS: Here's How Much $1000 Invested In T-Mobile US 10 Years Ago Would Be...
3	LLY, NVO: Eli Lilly's Closely Watched Obesity Pill Orforglipron Shows...
4	PTON, VSTM: Earnings Scheduled For August 7, 2025
5	LYV, CF: Apple Jumps, Eli Lilly Crashes On Worst Day In 2...
6	CVNA, AMZN: Carvana CEO Ernest Garcia, VP General...
7	XYZ, MCD: Nasdaq Surges Over 1% Amid Jum...

1	BLMN, MAX: Get Private Equity-Style Huge Returns Without The Massive Fees
2	QBTS: D-Wave Quantum's Cash Hoard Fuels Aggressive Expansion
3	LLY: Eli Lilly's Orforglipron Data Is Not Disastrous: Analyst
4	GRWG: Examining the Future: GrowGeneration's Earnings Outlook
5	PRSO: A Look at Peraso's Upcoming Earnings Report
6	TLS: A Peek at Telos's Future Earnings
7	QRHC: Earnings Preview For Quest Resource Holding